United States (National)
Not enough data
Steve Duffy's coverage is primarily focused on health, healthcare, and medical news in the local area of Port Talbot, United Kingdom. He often cites data and press releases to support his articles.
For a successful pitch to Steve Duffy, consider providing him with access to local experts or stakeholders within the healthcare sector who can discuss trends or provide insights into the challenges faced by NHS Wales. Additionally, if you have newsworthy data related to health issues in Port Talbot or exclusive information regarding drug pipeline updates that are relevant locally, it may capture his interest.
Given his focus on podcasts and entertainment alongside medical news topics such as drug pipeline updates and NHS Wales-related matters, he might also be interested in interviews with individuals involved in these sectors who can offer unique perspectives related to his coverage areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Tyenne is an interleukin-6 antagonist indicated for the treatment of various rheumatic disorders, chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome, and COVID-19 in certain hospitalized patients.
The table below is a review of notable updates that occurred in July 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
(tocilizumab-aazg) Injection 400mg/20mL (20mg/mL)20mL vials has been recalled by Fresenius Kabi after an investigation found glass particles.
Furoscix ReadyFlow (furosemide injection) Loop diuretic Treatment of edema in adults with heart failure or chronic kidney disease. FDA Approves Furosemide Autoinjector for At-Home Treatment of Edema in CHF, CKD
By: Steve Duffy
READ TIME: 2 MIN. Originally from Detroit, Joe Dombrowski has spent years building his voice in comedy—long before gaining national attention.
Drug Pharmacologic class Indication More information Cardiovascular Disease Mounjaro (tirzepatide)
The table below is a review of notable updates that occurred in August 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.
The table below is a review of notable updates that occurred in August 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
Mounjaro (tirzepatide) Dual glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist To reduce of the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus at high risk for these events. Mounjaro Approved to Reduce MACE Risk in Adults With T2DM
